Table 1.

Association of tumor-specific MHC-II/HLA-DR expression with outcome to durvalumab and NAC.

	RCB
	pCR (0)	I	II	III
	n (%)	n (%)	n (%)	n (%)
Total (n = 48)	20 (42%)	6 (13%)	16 (33%)	6 (13%)
HLA-DR ≥ 5% (n = 9)	6 (67%)	1 (11%)	1 (11%)	1 (11%)
HLA-DR < 5% (n = 39)	14 (36%)	5 (13%)	15 (38%)	5 (13%)
χ2 p value (1-tailed):	pCR vs. RD: P = 0.046‡	RCB 0/I vs. II/III: P = 0.057
Odds ratio for response (95% CI):	3.57 (0.87–14.23)	3.68 (0.81–18.81)

Abbreviation: CI, confidence interval.

^‡Trend for significance.